Table 2.
The baseline characteristics and laboratory findings of all patients according to LMCA minimum lumen area
| All patients (n = 205) |
MLA < 6 mm2 (n = 92) | MLA ≥ 6 mm2 (n = 113) | p value | ||
|---|---|---|---|---|---|
| Demographic characteristics | |||||
| Age, y | 61 (53–68) | 60 (55–70) | 61 (52–68) | 0.158 | |
| Male sex, % | 156 (76.1) | 72 (78.3) | 84 (74.3) | 0.512 | |
| Body mass index, kg/m2 | 26.8 (24.7–29) | 26 (24.2–28.6) | 27 (24.9–29) | 0.097 | |
| Comorbidites | |||||
| Hypertension, % | 129 (62.9) | 58 (63) | 71 (62.8) | 1.000 | |
| Diabetes mellitus, % | 48 (23.4) | 25 (27.2) | 23 (20.4) | 0.320 | |
| Hyperlipidemia, % | 60 (29.3) | 31 (33.7) | 29 (25.7) | 0.221 | |
| Smoking, % | 132 (64.4) | 56 (60.9) | 76 (67.3) | 0.380 | |
| Chronic kidney disease, % | 31 (15.1) | 14 (15.2) | 17 (15) | 1.000 | |
| Medications | |||||
| Acetylsalicylic Acid Use, % | 204 (99.5) | 92 (100) | 112 (99.1) | 1.000 | |
| P2Y12 Inh Use, % | Clopidogrel | 103 (50.2) | 50 (54.3) | 53 (46.9) | 0.327 |
| Ticagrelor | 44 (21.5) | 27 (29.3) | 17 (15) | ||
| Prasugrel | 16 (7.8) | 7 (7.6) | 9 (8) | ||
| B-Blocker Use, % | 191 (93.2) | 81 (85.9) | 110 (97.3) | 0.004 | |
| ACE Inh Use, % | 175 (85.4) | 70 (79.3) | 105 (93) | 0.003 | |
| Statin Use, % | 200 (97.6) | 91 (98.9) | 109 (96.5) | 0.382 | |
| OAD Use, % | 50 (24.4) | 27 (29.3) | 23 (20.4) | 0.145 | |
| Allopurinol Use, % | 16 (7.8) | 7 (7.6) | 9 (8) | 0.738 | |
| Clinical Presentation | |||||
| Acute Coronary Syndrome, % | 114 (55.6) | 60 (65.2) | 54 (47.8) | 0.074 | |
| Stable Angina Pectoris, % | 91 (44.4) | 32 (34.8) | 59 (52.2) | ||
| Laboratory assessment | |||||
| Hemoglobin, g/dl | 13.3 (12.1–14.5) | 13.1 (11.9–14.4) | 13.6 (12.2–14.5) | 0.630 | |
| eGFR, ml/min/1.73 m2 | 90.5 (70-101.6) | 92.5 (70-101.5) | 88.5 (70-101.6) | 0.995 | |
| Total cholesterol, mmol/L | 4.37 (3.74–5.3) | 4.26 (3.44–5.31) | 4.53 (3.88–5.37) | 0.084 | |
| Triglycerides, mmol/L | 1.56 (1.01–2.41) | 1.41 (0.97–2.16) | 1.62 (1.08–2.55) | 0.259 | |
| LDL cholesterol, mmol/L | 2.39 (1.78–3.33) | 2.29 (1.55–3.08) | 2.47 (1.84–3.51) | 0.096 | |
| HDL cholesterol, mmol/L | 1.07 (0.94–1.25) | 1.06 (0.91–1.24) | 1.08 (0.96–1.28) | 0.107 | |
| HbA1c, % | 5.78 (5.5–6.4) | 5.88 (5.5–6.4) | 5.69 (5.3–6.4) | 0.353 | |
| Uric asid, µmol/L | 477.4 (415.5-548.1) | 503.9 (446.4-565.8) | 468.5 (406.6-521.6) | 0.012 | |
| UHR, continuous variable | 446.3 (366-518.1) | 476.8 (405.5–560) | 414.9 (349.4–489) | < 0.001 | |
| UHR ≤ 450, categorical variable | 109 (53.2) | 35 (38) | 74 (65.5) | < 0.001 | |
| IVUS LMCA MLA, mm2 | 6.4 (4.8–9.1) | 4.8 (3.6–5.1) | 8.9 (6.7–11.6) | < 0.001 | |
| IVUS LMCA plaque burden, % | 58 (46–67) | 66.5 (64–71) | 47 (40–55) | < 0.001 | |
The data are presented as the median (interquartile range) or number (percentage) of patients. Abbreviations: ACE, angiotensin converting enzyme; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; IVUS, intravascular ultrasound; LDL, low-density lipoprotein; LMCA, left main coronary artery; MLA, minimal lumen area; OAD, oral antidiabetic; UHR, UA-to-HDL-C ratio